[1]Song G, Shi Y, Zhang M, et al. Global immune characterization of HBV/HCV-related hepatocellular carcinoma identifies macrophage and T-cell subsets associated with disease progression. Cell Discov,2020,6(1):90. [2]Schotten C, Ostertag B, Sowa JP, et al. GALAD score detects early-stage hepatocellular carcinoma in a European cohort of chronic hepatitis B and C patients. Pharmaceuticals (Basel),2021,14(8):735. [3]D'souza S, Lau KCK, Coffin CS, et al. Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma.World J Gastroenterol,2020,26(38):5759-5783. [4]Haberl EM, Feder S, Pohl R, et al. Chemerinis induced in non-alcoholic fatty liver disease and hepatitis B-related hepatocellular carcinoma. Cancers (Basel), 2020, 12(10): 2967. [5]Zhao L, Zhang X. Comments on “one‐carbon metabolism‐related micronutrients intake and risk for hepatocellular carcinoma: A prospective cohort study”.Int J Cancer,2021,(1):252-253. [6]Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: New trends.J Hepatol,2020,72(2):250-261. [7]Haberl EM, Weiss TS, Peschel G, et al. Liverlipids of patients with hepatitis B and C and associated hepatocellular carcinoma.Int J Mol Sci,2021,22(10):5297. [8]Dai X, Guo Y, Hu Y, et al. Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma.Theranostics,2021,11(7):3489-3501. [9]Tan RZH, Lockart I, Abdel Shaheed C, et al. Systematic review with meta‐analysis: The effects of non‐steroidal anti‐inflammatory drugs and anti‐platelet therapy on the incidence and recurrence of hepatocellular carcinoma.Aliment Pharmacol Ther,2021,54(4):356-367. [10] Sun J, Althoff KN, Jing Y, et al. Trends in hepatocellular carcinoma incidence and risk among persons with HIV in the US and Canada, 1996-2015.JAMA Netw Open,2021,4(2):e2037512. [11] 宋金云,赵宏宇,王建芳.慢性乙型肝炎和肝硬化患者血清HBV基因型分析.实用肝脏病杂志,2021,24(01):87-90. [12] Wangensteen KJ, Chang K M. Multiple roles for hepatitis B and C viruses and the host in the development of hepatocellular carcinoma.Hepatology,2021,73(Suppl 1):27-37. [13] Enomoto H, Ueno Y, Hiasa Y, et al. The transition in the etiologies of hepatocellular carcinoma-complicated liver cirrhosis in a nationwide survey of Japan.J Gastroenterol,2021,56(2):158-167. [14] 王成康,刘寿荣.血清HBV RNA在HBeAg阳性慢性乙型肝炎患者不同时期的表达水平及检测价值.临床肝胆病杂志,2021,37(12):2798-2801. [15] 刘婷婷,林玉婷,米拉,等.血清IL-33水平及其基因多态性与HBV感染临床转归的相关性.检验医学,2021,36(11):1101-1105. [16] Kim E, Viatour P. Hepatocellular carcinoma: old friends and new tricks.Exp Mol Med,2020,52(12):1898-1907. [17] Guo T, Gong C, Wu P, et al. LINC00662 promotes hepatocellular carcinoma progression via altering genomic methylation profiles.Cell Death Differ, 2020,27(7):2191-2205. [18] Burch BD, Godfrey AC, Gasdaska PY, et al. Interaction between FLASH and Lsm11 is essential for histone pre-mRNA processing in vivo in Drosophila.RNA,2011,17(6):1132-1147. [19] Wei S, Dai M, Zhang C, et al. KIF2C: a novel link between Wnt/β-catenin and mTORC1 signaling in the pathogenesis of hepatocellular carcinoma.Protein Cell,2021,12(10):788-809. [20] Li J, Li M, Wang T, et al. SLC38A4 functions as a tumour suppressor in hepatocellular carcinoma through modulating Wnt/β-catenin/MYC/HMGCS2 axis. Br J Cancer, 2021, 125(6): 865-876. |